Form 4: MBX Biosciences Director James M. Cornelius Reports Conversion of Preferred Stock to Common Stock

Director James M. Cornelius reported the conversion of Series A and Series B Convertible Preferred Stock into Common Stock immediately prior to MBX Biosciences' initial public offering on September 16, 2024.

Summary

• On September 16, 2024, James M. Cornelius, a director of MBX Biosciences, Inc., reported transactions related to the conversion of preferred stock into common stock.
• The transactions involved the conversion of Series A and Series B Convertible Preferred Stock into common stock immediately prior to the company's initial public offering.
• 102,082 shares of Common Stock were directly owned.
• 994,069 shares of Series A Convertible Preferred Stock were converted into 82,686 shares of Common Stock.
• 233,192 shares of Series B Convertible Preferred Stock were converted into 19,396 shares of Common Stock.

Sentiment

Score: 7

Explanation: The document is a standard regulatory filing related to an IPO, indicating a neutral to slightly positive sentiment as it reflects a key step in the company's public offering process.

Industry Context

Form 4 filings are standard practice when company insiders, like directors, engage in transactions involving the company's securities. This filing reflects changes in beneficial ownership due to the conversion of preferred stock in anticipation of the company's IPO.

Stakeholder Impact

• The conversion of preferred stock to common stock impacts shareholders by increasing the number of common shares outstanding.
• This conversion is a standard procedure before an IPO and is generally expected by investors.

Key Dates